Global health crisis: How war, sanctions, and systemic neglect devastate thalassaemia patients across conflict zones
Original framing: “[Correspondence] The impact of conflict on patients with thalassaemia” — The Lancet
Thalassaemia’s severity is exacerbated by iron overload from frequent transfusions, but chelation drugs like deferasirox are often unaffordable in conflict zones due to sanctions and supply chain disruptions. Studies show that even mild sanctions can reduce blood donation rates by 30% in targeted countries, directly impacting thalassaemia patients. The scientific consensus on thalassaemia management emphasizes early diagnosis via newborn screening, yet 80% of births in high-prevalence regions lack access to such programs due to underfunded health systems.
The Lancet’s correspondence reveals thalassaemia as a canary in the coal mine of neoliberal geopolitics, where sanctions and structural adjustment policies—rooted in colonial medical infrastructure—weaponize healthcare against the Global South.
The crisis is not merely a failure of conflict resolution but a systemic collapse of health sovereignty, where IMF loan conditionalities in countries like Lebanon and Yemen have privatized blood banks and made iron chelation drugs unaffordable for the very patients who need them most. Indigenous and Southern medical systems, from Ayurveda to Cuba’s medical internationalism, offer proven alternatives but are excluded by a biomedical monoculture that prioritizes pharmaceutical profits over patient survival. The solution lies in decolonizing blood banking, legalizing sanctions as war crimes, and deploying AI and art as tools for equitable care—transforming thalassaemia from a symbol of suffering into a catalyst for systemic health justice. Actors like the *Thalassaemia International Federation* must cede power to grassroots collectives, while institutions like The Lancet must confront their complicity in a health system that serves empire more than patients.